PT-141 (Bremelanotide): Melanocortin Sexual Function Peptide — FDA-Approved for 1 Indication, Used Off-Label for 2 Genders

PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist that activates sexual arousal through central nervous system pathways — a fundamentally different mechanism from PDE5 inhibitors (Viagra, Cialis) which work through peripheral vascular effects.

PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its off-label use for men with low libido and for postmenopausal women reflects the same mechanism applied to patients outside the approved indication. The melanocortin pathway it activates — specifically MC3R and MC4R receptors in the brain — is centrally involved in sexual motivation and arousal for both men and women.

At Rebuild Regen Medical Clinic, PT-141 is available as part of the ED treatment program and as a standalone option for patients of any gender with documented low sexual desire that has not responded to hormonal correction alone.

What PT-141 Is — Melanocortin Receptor Agonism and CNS-Based Arousal

Melanocortin receptors (MCR1 through MCR5) are distributed throughout the brain and peripheral tissues. MC3R and MC4R are located in the hypothalamus and limbic system — brain regions involved in sexual behavior, motivation, and arousal.

PT-141 activates these central receptors, producing an increase in sexual motivation and arousal that operates independently of peripheral vascular function. This is why PT-141 works in some patients where PDE5 inhibitors have been insufficient or are contraindicated — the mechanism is not vascular.

For men, PT-141 increases the motivational/desire component of sexual function rather than the mechanical vascular response. For patients where reduced libido is the primary complaint rather than erectile mechanics, this distinction is clinically relevant.

For women, the FDA approval in HSDD reflects the same CNS mechanism — increased sexual desire through hypothalamic activation. Many women with libido reduction related to perimenopause, postmenopause, or hormonal changes experience meaningful benefit from PT-141 even after hormonal correction has been optimized.

Clinical Applications at Rebuild Regen

ED treatment protocol: PT-141 is one of three components in the ED treatment program at Rebuild Regen, alongside acoustic wave therapy and the P-Shot (PRP). Where acoustic wave therapy addresses vascular remodeling and the P-Shot delivers PRP growth factors to penile tissue, PT-141 addresses the desire and arousal component centrally. Combined, the three modalities address ED from different mechanistic angles.

Female sexual dysfunction: For women experiencing reduced libido associated with perimenopause, menopause, hormonal changes, or HSDD, PT-141 provides a CNS-based desire signal that hormonal therapy alone does not always produce.

Post-hormonal-correction libido support: Some patients who have undergone hormone replacement or TRT protocols find that even after hormonal levels are optimized, libido does not fully recover. In these cases, PT-141 addresses the central motivational component that may persist as an issue beyond the hormonal deficit.

Administration

PT-141 is administered subcutaneously, typically 45 to 60 minutes before anticipated sexual activity. The FDA-approved dosing for women (Vyleesi) is 1.75 mg. Off-label dosing for men and in other contexts is individualized by Elizabeth based on clinical assessment.

PT-141 is not a daily medication. It is an on-demand compound, used as needed rather than on a continuous protocol.

Frequently Asked Questions

How is PT-141 different from Viagra?

Viagra (sildenafil) and other PDE5 inhibitors work by increasing blood flow to the penis through vascular mechanisms. PT-141 works through the brain's melanocortin receptors to increase sexual desire and arousal. The two mechanisms are independent and complementary — some patients benefit from combining them, though this is evaluated on a case-by-case basis.

Does PT-141 work for women?

PT-141 is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi. Clinical data supports its use in women across multiple hormonal states for the desire/arousal component of sexual function. Elizabeth evaluates each female patient's full hormonal picture before prescribing.

Are there side effects?

The most common side effects include nausea (most common, reported in approximately 40% of users in the FDA approval trials, typically mild and transient), flushing, and mild increases in blood pressure. Elizabeth reviews these effects during the consultation and addresses the clinical context.

When PT-141 Is Not Appropriate

PT-141 is not appropriate for patients with uncontrolled hypertension (it produces a transient blood pressure increase), cardiovascular disease requiring careful blood pressure management, pregnancy, or patients taking antihypertensive medications that are significantly affected by blood pressure fluctuation. Elizabeth evaluates cardiovascular status before prescribing.

Rebuild Regen Medical Clinic 3320 N Federal Hwy #101, Lighthouse Point, FL 33064 (954) 953-4208 | rebuildregenmedical.com

Back to Peptide Therapy | ED Treatments | Schedule a Consultation